Bharat Biotech Stresses Covaxin's Safety First Approach and Efficacy

Bharat Biotech, a leading vaccine manufacturer, recently emphasized the safety profile of its Covid-19 vaccine, Covaxin, highlighting its absence of adverse side effects. This announcement comes in the wake of AstraZeneca's acknowledgment that its vaccine, Covishield, could potentially lead to complications in rare instances. Bharat Biotech's statement underlines Covaxin's development focus on safety, followed by efficacy, setting it apart in the landscape of Covid-19 vaccines.

Representative image

The company detailed the extensive evaluation Covaxin underwent, involving over 27,000 participants during its licensure process. It was granted restricted use in clinical trial mode, which included comprehensive safety reporting across several hundred thousand subjects. The Union Ministry of Health also evaluated the vaccine, ensuring a thorough review process.

Moreover, Bharat Biotech continued safety monitoring and pharmacovigilance throughout Covaxin's product lifecycle. The outcomes of these studies and follow-up activities have confirmed Covaxin's robust safety profile, with no incidents related to blood clots, thrombocytopenia, TTS (thrombosis with thrombocytopenia syndrome), VITT (vaccine-induced immune thrombotic thrombocytopenia), pericarditis, or myocarditis reported.

The company also pointed out its commitment to prioritizing safety in vaccine development. This approach stems from an understanding that while the efficacy of Covid-19 vaccines might wane over time, their impact on patient safety is enduring. Bharat Biotech takes pride in Covaxin being the only Covid-19 vaccine within the Government of India's immunisation programme to have undergone efficacy trials within the country.

This statement from Bharat Biotech follows shortly after AstraZeneca's court admission regarding the potential for very rare cases of thrombosis with thrombocytopenia syndrome associated with its vaccine. Covishield, as it is known in India, was produced by the Serum Institute of India under license from AstraZeneca.

Bharat Biotech's reassurance about Covaxin's safety profile aims to bolster public confidence in vaccination efforts against Covid-19. As vaccination remains a critical tool in combating the pandemic, such affirmations from vaccine manufacturers play a vital role in guiding public health decisions and policy.